Research programme: cardiovascular disorders therapeutics - InVasc Therapeutics

Drug Profile

Research programme: cardiovascular disorders therapeutics - InVasc Therapeutics

Alternative Names: INV 40-69; INV 55-05; INV 55-06; INV 65-05; INV 65-06; INV 70-65; INV 74-65; INV-065

Latest Information Update: 06 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator InVasc Therapeutics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Metabolic syndrome; Peripheral arterial disorders

Most Recent Events

  • 01 Apr 2008 Preclinical trials in Atherosclerosis in USA (unspecified route)
  • 01 Apr 2008 Preclinical trials in Metabolic syndrome in USA (unspecified route)
  • 01 Apr 2008 Preclinical trials in Peripheral arterial disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top